Results of paired t-Tests comparing follow-up QoL with baseline QoL and with recalled QoL on ten scales of the EORTC QLQ-C30, QLQ-BR23.

<p>Results of paired t-Tests comparing follow-up QoL with baseline QoL and with recalled QoL on ten scales of the EORTC QLQ-C30, QLQ-BR23.</p

Results of paired t-Tests comparing baseline QoL and recalled QoL on ten scales of the EORTC QLQ-C30, QLQ-BR23.

<p>Results of paired t-Tests comparing baseline QoL and recalled QoL on ten scales of the EORTC QLQ-C30, QLQ-BR23.</p

Summary of measures including time points.

<p>Summary of measures including time points.</p

Baseline QoL, Follow-up QoL, and Recalled QoL on Ten Scales of the EORTC QLQ-C30, QLQ-BR23.

<p>Baseline = first questionnaire filled in 0 to 2 days before discharge from hospital; follow-up = about 7 years after baseline; recall = recollection of baseline QoL about 7 years later; GQ = global QoL; PF = physical functioning; RF = role functioning; EF = emotional functioning; CF = cognitive functioning; SF = social functioning; FA = fatigue; PA = pain; AS = arm symptoms; higher scores mean better QoL, reference values can be found in Hinz et al [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0171519#pone.0171519.ref020" target="_blank">20</a>].</p

Additional file 3: Table S2. of Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

Malignant melanoma patients aged 35 years and above by age at diagnosis, sex, UICC stage, year of diagnosis, place of residence and ‘diagnosis during screening’, N = 34 739 (UICC 0 and X excluded) (DOCX 40 kb

Additional file 4: Table S3. of Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

Relative 5-year survival of malignant melanoma patients diagnosed between 2002 and 2011, overall (UICC 0-IV, X) (N = 60 672) and for patients with invasive tumours (UICC I – IV, X) stratified by age, sex, UICC stage, ‘diagnosis during screening’ and place of residence (N = 49 351) (DOCX 39 kb